MBA Jack Weinstein appointed CEO
Jeremy Meinen Appointed CPA and Chief Financial Officer
Geneva, Switzerland / Accesswire / 8 December 2022 / RELIEF THERAPEUTICS Holding SA (SIX: RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (“Relief”) is a Swiss commercial-stage biopharmaceutical company with a portfolio of select specialty, rare and (MBA) as Chief Executive Officer (CEO) and Jeremy Meinen (CPA) as Chief Financial Officer (CFO).
“I am humbled and honored to take on greater responsibility as CEO of Relief,” said Weinstein. I look forward to taking a more active role.” Relief has now officially launched its first commercial product, PKU GOLIKE ® The settlement of the litigation with NRx Pharmaceuticals will allow the company to shift its focus to further develop Relief’s strategic direction and plans. ”
“Jeremy has proven himself to be a skilled and competent financial professional since joining Relief,” said Weinstein. “His contributions to our financial reporting and resource allocation decisions are expected to be important in driving our growth forward.”
About Jack Weinstein
Jack Weinstein, MBA, joined Relief in October 2020 as US-based Chief Financial Officer and Treasurer. He brings over 40 years of extensive business management expertise as a chief financial officer, investment banker, and consultant in the biopharmaceutical industry. He has extensive experience in financial and healthcare investment banking, corporate and business development, and US Food and Drug Administration regulatory and intellectual property strategy. Mr. Weinstein has successfully completed a variety of corporate finance transactions, including public and private financings, mergers and acquisitions. Prior to joining Relief, he was Managing Director and Head of Healthcare Investment Banking at Avalon Group, Ltd., an independent boutique investment bank based in New York. Prior to that, he served as Chief Financial Officer, Treasurer and Vice President of Business Development at Catalyst Pharmaceuticals, Inc., a biopharmaceutical company that develops prescription drugs, and led the company’s listing on the Nasdaq. . Previously, Mr. Weinstein was President and Founder of The Starlington Group, a consulting firm that provides strategy, business development, regulatory and CFO consulting services, where he advised on mergers and acquisitions and raised equity and debt for mid-market companies. I was going He also has experience in several other investment banking and consulting firms.
Mr. Weinstein graduated with a master’s degree in business administration from Harvard Business School and a BM degree from the University of Miami. honor student Mr. Weinstein holds a FINRA Series 79 (Investment Banking Representative Examination) and 63 (Uniform Securities State Law Examination) license.
About Jeremy Meinen
CPA Jeremy Meinen joined Relief in April 2020 as Interim Chief Financial Officer. Prior to joining Relief, Mr. Meinen provided financial consulting, management and auditing services to companies in various industries. He started his career at an international audit firm, where he held positions of increasing responsibility and scope for over six years.
Mr. Meinen holds a Master of Science in Finance from the University of Bocconi and a Bachelor of Business Administration from the University of Geneva. He is a Swiss Chartered Accountant and former Chartered Auditing Professional.
Relief is a Swiss commercial company focused on the identification, development and commercialization of novel, patent-protected products for the treatment of rare and ultra-rare diseases such as metabolic disorders, pulmonary diseases and connective tissue disorders. is a staged biopharmaceutical company. Relief’s diverse pipeline consists of assets, such as PKU GOLIKE, that have the potential to effectively address critical unmet medical needs. ® This is the first sustained-release amino acid product to be commercialized for the dietary management of phenylketonuria (“PKU”). Relief is urea cycle disorder (“UCD”) and maple syrup urine disease (“MSUD”). Relief also continues to develop Aviptadil for several rare pulmonary indications.In addition, Relief has APR-TD011 in clinical development. APR-TD011 is a differentiated acid-oxidizing solution of hypochlorous acid intended for the treatment of epidermolysis bullosa (“EB”). APR-TD011 has received orphan drug designation from the FDA. Finally, Relief commercializes some legacy products through licensing and distribution partners.
RELIEF THERAPEUTICS Holding SA is listed on the Swiss Stock Exchange under the symbol RLF and in the USA on the OTCQB under the symbols RLFTF and RLFTY.
For more information, please visit www.relieftherapeutics.com. You can also follow Relief on LinkedIn.
RELIEF THERAPEUTICS Holding SA
Vice President of IR & Communications
Life Science Advisor
This communication contains, expressly or impliedly, certain forward-looking statements regarding RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks, uncertainties and other factors. This includes risks described in RELIEF THERAPEUTICS Holding SA’s filings with SIX and the US Securities and Exchange Commission. RELIEF THERAPEUTICS Holding SA does not materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements; RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
sauce: Relief Therapeutics Holdings AG
View source version on accesswire.com: